This ultimately boosts cytotoxic T lymphocyte infiltration and recognition capacity in microsatellite-stable CRC, thereby elevating the tumor inhibition rate of programmed cell death protein 1 therapy from 5% to 69% [102]. This evidence concerns the gene PDCD1 and neoplasm.